Nuveen’s DexCom DXCM Stock Holding History

Nuveen’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,800	Closed	-$2K	–	3206
2022 Q3	$2K	Buy	+26,800	New	+$2.27M	﹤0.01%	3256

Other funds holding DXCM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Nuveen's DXCM Position: Q3 2026 in Review

Nuveen increased its DexCom (DXCM) stake by 141% in Q3 2026, buying an estimated $215M and bringing the position to 4,411,504 shares worth $381M. The position accounts for 0.09% of the portfolio, ranked #165.

Nuveen first reported a position in DXCM in Q4 2013 and has held it in 49 quarters since. The position peaked at $1.15B in Q3 2021. 863 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

Nuveen held 4,411,504 shares of DexCom worth $381M as of Q3 2026.
Nuveen bought 2,581,269 DexCom shares in Q3 2026, an estimated $215M.
DexCom made up 0.09% of Nuveen's portfolio in Q3 2026, its #165 holding.
Nuveen first reported a position in DexCom in Q4 2013 and has held it in 49 quarters since.
Nuveen's DexCom position peaked at $1.15B in Q3 2021.
863 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.